This test identifies specific genetic variants (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313) that influence your response to GLP-1 compounds, enabling your provider to personalize your therapy and address overeating at the genetic level rather than through trial and error
The risk of constipation may be dose-dependent, often emerging or worsening during dose escalation phases
doi: 10.1007/s11306-016-1145-z 199 RizzattiGLopetusoLRGibiinoGBindaCGasbarriniA
In person in Katy, TX or virtually wherever you are
Purpose-built for physicians GLP-1 receptor agonists may help teens with obesity maintain weight loss Teens with severe obesity who lost weight maintained more of their weight loss with use of a GLP-1 receptor agonist plus lifestyle therapy compared with lifestyle therapy alone, according to study findings published in Obesity
The combined effects can increase the risk for sarcopenia the gradual loss of muscle mass, strength, and function